Oral surgery, oral medicine, oral pathology and oral radiology · 2026
Oral adverse events associated with anti-tumor necrosis factor-alpha therapies: using a large real-world dataset.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Oyewole Stella O, Olawuyi Adetokunbo B, Okhuaihesuyi Osariemen, Owosho Adepitan A
Аннотация
BACKGROUND: Anti-tumor necrosis factor-alpha (anti-TNF-α) therapies are efficacious in managing immune-mediated inflammatory diseases, however, long-term use has been associated with notable adverse events. As patients use expands, understanding the spectrum of oral adverse events (OAEs) has become essential.
MATERIALS AND METHODS: We conducted a retrospective cohort study using the TriNetX research network. A 5‑year observation window identified patients prescribed anti‑TNF-α therapies. Patients with prior oral conditions, concurrent cancer therapies, or antiresorptive exposure were excluded. OAEs were categorized into xerostomia, mucosal disorders, infectious disorders, gingival hyperplasia, medication-related osteonecrosis of the jaw (MRONJ), and oral squamous cell carcinoma (OSCC). Propensity score matching (1:1, age/sex) compared anti‑TNF-α users with unexposed controls.
RESULTS: In a cohort of 1,645,751 individuals receiving anti‑TNF‑α therapy, OAEs were frequent, with oral lichenoid lesions (1.27%, 20,135), candidiasis (1.09%, 17,475), xerostomia (0.87%, 14,024), stomatitis (0.68%, 10,904), and oral herpes (0.39%, 6,343) most commonly observed. Less frequent events included MRONJ (0.01%, 173), gingival hyperplasia (0.02%, 285), and OSCC (0.07%, 1,074). Compared with the general population, anti‑TNF‑α therapy significantly increased the odds of most mucosal and infectious conditions (P < .001), though oral lichen planus showed no association. Interestingly, OSCC exhibited an inverse association (OR = 0.75, P < .0001), suggesting a potential protective effect.
CONCLUSION: These findings highlight the importance of routine oral health surveillance and robust pharmacovigilance amongst patients on anti‑TNF-α therapies.
MATERIALS AND METHODS: We conducted a retrospective cohort study using the TriNetX research network. A 5‑year observation window identified patients prescribed anti‑TNF-α therapies. Patients with prior oral conditions, concurrent cancer therapies, or antiresorptive exposure were excluded. OAEs were categorized into xerostomia, mucosal disorders, infectious disorders, gingival hyperplasia, medication-related osteonecrosis of the jaw (MRONJ), and oral squamous cell carcinoma (OSCC). Propensity score matching (1:1, age/sex) compared anti‑TNF-α users with unexposed controls.
RESULTS: In a cohort of 1,645,751 individuals receiving anti‑TNF‑α therapy, OAEs were frequent, with oral lichenoid lesions (1.27%, 20,135), candidiasis (1.09%, 17,475), xerostomia (0.87%, 14,024), stomatitis (0.68%, 10,904), and oral herpes (0.39%, 6,343) most commonly observed. Less frequent events included MRONJ (0.01%, 173), gingival hyperplasia (0.02%, 285), and OSCC (0.07%, 1,074). Compared with the general population, anti‑TNF‑α therapy significantly increased the odds of most mucosal and infectious conditions (P < .001), though oral lichen planus showed no association. Interestingly, OSCC exhibited an inverse association (OR = 0.75, P < .0001), suggesting a potential protective effect.
CONCLUSION: These findings highlight the importance of routine oral health surveillance and robust pharmacovigilance amongst patients on anti‑TNF-α therapies.